IDiyas

For the Inventor, By the Inventor

San Bruno, CA, United States of America

Cameron Smith

USPTO Granted Patents = 33 

 

Average Co-Inventor Count = 5.0

ph-index = 11

Forward Citations = 318(Granted Patents)


Location History:

  • Burlingame, CA (US) (2012 - 2017)
  • South San Francisco, CA (US) (2020 - 2021)
  • San Bruno, CA (US) (2017 - 2024)

Company Filing History:

goldMedal28 out of 262 
 
Theravance Biopharma R&d Ip, LLC
 patents
silverMedal5 out of 386 
 
Theravance, Inc.
 patents

Years Active: 2012-2025

Loading Chart...
Loading Chart...
33 patents (USPTO):Explore Patents
1. 12398135 - Dimethyl amino azetidine amides as JAK inhibitors (2025-08-26),
2. 12384761 - Imidazolo indazole compounds as JAK inhibitors (2025-08-12),
3. 11878977 - JAK inhibitors containing a 4-membered heterocyclic amide (2024-01-23),
4. 11718616 - JAK kinase inhibitor compounds for treatment of respiratory disease (2023-08-08),
5. 11713315 - 5 to 7 membered heterocyclic amides as JAK inhibitors (2023-08-01),
6. 11667637 - Fused imidazo-piperidine JAK inhibitors (2023-06-06),
7. 11634419 - Dimethyl amino azetidine amides as JAK inhibitors (2023-04-25),
8. 11453668 - JAK inhibitors containing a 4-membered heterocyclic amide (2022-09-27),
9. 11299492 - JAK kinase inhibitor compounds for treatment of respiratory disease (2022-04-12),
10. 11254669 - Fused imidazo-piperidine JAK inhibitors (2022-02-22),
11. 10954237 - JAK inhibitors containing a 4-membered heterocyclic amide (2021-03-23),
12. 10947229 - Dimethyl amino azetidine amides as JAK inhibitors (2021-03-16),
13. 10836763 - 5 to 7 membered heterocyclic amides as JAK inhibitors (2020-11-17),
14. 10550118 - JAK inhibitors containing a 4-membered heterocyclic amide (2020-02-04),
15. 10526330 - JAK kinase inhibitor compounds for treatment of respiratory disease (2020-01-07),

Cameron Smith: Innovator in JAK Kinase Inhibitors

Introduction

Cameron Smith is a prolific inventor based in San Bruno, CA, who has made significant contributions in the field of pharmaceutical innovations with a focus on JAK inhibitors. With an impressive portfolio of 31 patents, Smith has been at the forefront of developing novel compounds that address critical health issues.

Latest Patents

Among his latest inventions, Cameron Smith has developed compounds that incorporate a 4-membered heterocyclic amide, which are particularly useful as JAK kinase inhibitors. These compounds can be formulated in different pharmaceutical compositions aimed at treating respiratory diseases. His patents highlight methods of using these compounds effectively and detail processes for their preparation.

Career Highlights

Throughout his career, Cameron Smith has worked with leading companies in the biopharmaceutical sector, including Theravance Biopharma R&D, LLC and Theravance, Inc. His innovative contributions have been instrumental in advancing research and development within these organizations, focusing on impactful therapeutics.

Collaborations

Cameron has collaborated with skilled professionals in his field, including his coworkers Paul Ross Fatheree and Steven D. E. Sullivan. These partnerships have fostered an environment of creativity and innovation, allowing for the development of cutting-edge solutions to pressing medical challenges.

Conclusion

Cameron Smith's dedication to innovation in pharmaceutical sciences, particularly in the domain of JAK inhibitors for respiratory diseases, underscores the vital role of inventors in advancing healthcare. His extensive patent portfolio reflects his commitment to developing transformative therapies that have the potential to benefit many patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…